Think Before You Ink... New Poll Shows Opposite Sex May Prefer You Tatt-Free

WAYLAND, Mass., July 21 /PRNewswire/ -- While Angelina Jolie may boast yet another tattoo, a new survey shows 47 percent of men find tattoos on women to be a turn off.  The same Ask Jeeves survey also reveals as many as 38 percent of women feel the same way about men with tattoos.  The FDA estimates that 45 million Americans have at least one tattoo and an estimated 50 percent of individuals with tattoos, eventually grow dissatisfied and want them removed.  

In the past, the only options for removing tattoos were dermabrasion and excision – neither was entirely effective and both were painful.  But thanks to the latest advancements in science and technology, there are now pigment-specific lasers that can target more colors than ever before.  "I'm seeing more and more people of all ages with tattoo regret – often right after they get their new ink," said Dr. Eric Bernstein, board certified dermatologist at the Centers For Cosmetic Laser Surgery in Ardmore Philadelphia. "The AlexTriVantage® laser enables me to address multi-colored tattoos – which seem to be more and more popular today.  It's really gratifying to be able to reverse a bad decision for people who thought their choice of art was permanent."

The AlexTriVantage laser with Candela's proprietary "Laser Pumped Laser" technology raises the bar for tattoo-removal lasers to new heights with its versatility and advanced delivery system.  Previously, removing multi-colored tattoos meant using multiple lasers.  The AlexTriVantage extends the capabilities of traditional Q-switched Alexandrite lasers by offering practitioners the freedom to treat all colors using three unique wavelengths, 755 nm, 1064 nm and 532 nm, all in one system.  In addition, the AlexTriVantage state-of-the-art energy delivery emits a precise, and uniform beam resulting in minimal bleeding, tissue splatter or scarring.

To learn more about the AlexTriVantage®, including the latest clinical data, before and after photos or to locate a physician, visit www.candelalaser.com.

About Syneron Medical Ltd.

Candela Corporation is a wholly-owned subsidiary of Syneron Medical Ltd – a company devoted to real technology, real science and real results -- is the leading global aesthetic device company with a comprehensive product portfolio and a global distribution footprint. The Company's technology enables physicians to provide advanced solutions for a broad range of medical-aesthetic applications including body contouring, hair removal, wrinkle reduction, rejuvenation of the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. The Company sells its products under two distinct brands, Syneron and Candela. Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Medical Ltd. are located in Israel. Syneron also has R&D and manufacturing operations in the US. The company markets and services and supports its products in 86 countries. It has offices in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan, and Hong Kong and distributors worldwide.

Additional information can be found at www.syneron.com.

SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS

Any statements contained in this document regarding future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Further, any statements that are not statements of historical fact (including statements containing "believes," "anticipates," "plans," "expects," "may," "will," "would," "intends," "estimates" and similar expressions) should also be considered to be forward-looking statements.  There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including the risk that the businesses of Syneron and Candela may not be integrated successfully; the risk that the merger transaction with Candela may involve unexpected costs or unexpected liabilities; the risk that synergies from the merger transaction may not be fully realized or may take longer to realize than expected; the risk that disruptions from the merger transaction make it more difficult to maintain relationships with customers, employees, or suppliers; as well as the risks set forth in Syneron Medical Ltd.'s most recent Annual Report on Form 20-F, and the other factors described in the filings that Syneron Medical Ltd. makes with the SEC from time to time.  If one or more of these factors materialize, or if any underlying assumptions prove incorrect, Syneron Medical Ltd.'s actual results, performance or achievements may vary materially from any future results, performance or achievements expressed or implied by these forward-looking statements.

In addition, the statements in this document reflect the expectations and beliefs of Syneron Medical Ltd. as of the date of this document.  Syneron Medical Ltd. anticipates that subsequent events and developments will cause its expectations and beliefs to change.  However, while Syneron Medical Ltd. may elect to update these forward-looking statements publicly in the future, it specifically disclaims any obligation to do so.  The forward-looking statements of Syneron Medical Ltd. do not reflect the potential impact of any future dispositions or strategic transactions that may be undertaken.  These forward-looking statements should not be relied upon as representing Syneron Medical Ltd.'s views as of any date after the date of this document.

SOURCE Syneron Medical Ltd.